Armin Novak

Mr. Armin Novak

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CPCamilla Passi
Camilla Passi
ANArmin Novak
Armin Novak
Marc SchneiderMarc Schneider
Marc Schneider
SLSangeun Lee
Sangeun Lee
Polymer–drug conjugates (PDCs) represent an advanced drug delivery strategy designed to address critical limitations of conventional therapeutics, including poor water solubility, rapid systemic clearance, and off-target toxicity. By covalently linking therapeutic agents to polymeric carriers through rationally designed linkers, PDCs enable improved pharmacokinetic profiles, enhanced stability, and controlled drug release. This review provides a comprehensive overview of the key design principles governing PDC systems, with a particular focus on the role of biofunctional polymers. Essential parameters for polymer selection, including biocompatibility, biodegradability, molecular weight, and functional group availability, are discussed in relation to their influence on drug loading, release kinetics, and biological performance. In addition, both natural and synthetic polymers are evaluated for their ability to improve solubility, modulate biodistribution, and reduce systemic toxicity. An overview of stimuli-responsive PDCs is provided, including pH-, redox-, and temperature-sensitive systems, which enable site-specific and spatiotemporally controlled drug release in response to pathological microenvironments. We emphasize the special role of bioactive polymers such as poly-lysine, hyaluronic acid, chitosan, and gelatin for their intrinsic biological activity, including receptor-mediated targeting, antimicrobial activity, and synergistic therapeutic effects. These properties support the development of dual-active conjugates with enhanced specificity and efficacy. Overall, this review underscores the transition of polymers from passive carriers to active therapeutic components and outlines current challenges and future perspectives for the clinical translation of next-generation PDCs.

20 February 2025 in Macromolecular Chemistry and Physics
Verified
Journal Article
Open access
ANArmin Novak
Armin Novak
SPStefan V. Pochmann
Stefan V. Pochmann
AHAlexander Horn
Alexander Horn
AWAgnes-Valencia Weiss
Agnes-Valencia Weiss
Marc SchneiderMarc Schneider
Marc Schneider
With a steadily rising number of novel biopharmaceuticals in development, the demand for applicable delivery systems for macromolecular drugs persists. Polymeric nanoparticles, consisting of the natural product gelatin, present beneficial attributes for this application. To stabilize those nanoparticles without interfering with encapsulated macromolecules, surface‐crosslinked gelatin particles are developed and thoroughly characterized for their physicochemical and mechanical properties. With only limited data available for the latter, investigating the elastic properties can offer a more comprehensive understanding of the crosslinking processes involved and of the gelatin particles’ potential applications. In this study, protocols for surface‐crosslinked gelatin particles type A (GNP‐A) and B (GNP‐B) are described. Significant differences between the two types of gelatin are reported regarding their physicochemical and mechanical properties. GNP‐A consists of a lower crosslinking degree, leading to pronounced swelling in aqueous environments and softer nanoparticles. They possess contrary properties compared to the more extensively crosslinked and stiffer GNP‐B. However, this doesn't affect encapsulation efficiency, allowing to develop nanoparticulate systems suitable for various applications by adjusting the particle properties while maintaining the same drug load. These findings provide a deeper understanding of polymeric gelatin particles and reveal the importance of investigating the mechanical properties of drug delivery systems during pharmaceutical development.

2 November 2026 in npj Viruses
Verified
Journal Article
Open access
PDF file
JTJolly Thomas
Jolly Thomas
CNChristoph André Nilius
Christoph André Nilius
LMLeon Matis
Leon Matis
SSSabrina Schnur
Sabrina Schnur
AHAnja Himmelstein
Anja Himmelstein
DLDaniel Christian Lauster
Daniel Christian Lauster
The nasal mucosa is an important site of influenza virus entry and early replication, yet approved antivirals are not designed for nasal delivery. This Review summarizes antiviral strategies suitable for nasal administration and evaluates animal and human-relevant models for their development. We discuss route-specific formulation and regulatory requirements and propose a translational framework integrating in vitro, ex vivo and microphysiological systems with targeted in vivo studies to reduce animal use.